Seattle Genetics Highlights ADCETRIS A Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting -Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients- -ADCETRIS ... (more)
http://www.businesswire.com/news/topix/20121210005426/en
http://www.businesswire.com/news/topix/20121210005426/en
No comments:
Post a Comment